You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Balancing Efficacy and Safety in Schizophrenia: Current and Emerging Approaches

  • Authors: Christoph U. Correll, MD
  • CME / ABIM MOC Released: 8/2/2021; Reviewed and Renewed: 9/14/2022
  • Valid for credit through: 9/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists and primary care providers (PCPs) involved in the care of patients with schizophrenia.

The goal of this activity is to help clinicians increase their awareness of the spectrum of symptoms associated with schizophrenia, the uses and limitations of current antipsychotic medications, and the rationale and clinical data for investigational therapies being studied for the management of schizophrenia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Factors to consider for individualizing the selection of an antipsychotic therapy for the management of schizophrenia 
    • Limitations associated with currently available antipsychotic medications 
    • Clinical trial data for investigational antipsychotic therapies being studied for the management of schizophrenia 


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Christoph U. Correll, MD

    Professor
    Department of Psychiatry and Molecular Medicine
    Donald and Barbara Zucker School
    of Medicine at Hofstra/Northwell
    Hempstead, New York, United States
    Professor and Chair
    Department of Child and Adolescent Psychiatry
    Charité University Medicine
    Berlin, Germany

    Disclosures

    Disclosure: Christoph U. Correll, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acadia; Alkermes; Allergan; Angelini; Gedeon Richter; Intra-Cellular Therapies; Janssen/Johnson & Johnson; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedinCell; Merck; Mitsubishi Tanabe Pharma; Mylan; Neurocrine; Noven; Otsuka; Pfizer; Recordati; ROVI; Sumitomo Dainippon; Sunovion; Supernus; Takeda; Teva
    Served as a speaker or a member of a speakers bureau for: Angelini; Gedeon Richter; Janssen/Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma; Mylan; Otsuka; Recordati; Sumitomo Dainippon; Sunovion
    Received grants for clinical research from: Janssen; Takeda
    Owns stock, stock options, or bonds from: LB Pharma
    Other: DSMB member or chair: Lundbeck; Relmada; ROVI; Teva

Steering Committee

  • Leslie Citrome, MD, MPH

    Clinical Professor of Psychiatry and Behavioral Sciences
    New York Medical College
    Valhalla, New York

    Disclosures

    Leslie Citrome, MD, MPH Clinical Professor of Psychiatry and Behavioral Sciences New York Medical College Valhalla, New York Disclosure: Leslie Citrome, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Forum Pharmaceuticals; Indivior PLC; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA; Vanda Pharmaceuticals Inc.
    Served as a speaker or a member of a speakers bureau for: ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA; Vanda Pharmaceuticals Inc.
    Owns stock, stock options, or bonds from: Bristol Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Merck & Co., Inc.; Pfizer Inc.

  • Christoph Correll, MD

    Professor of Psychiatry and Molecular Medicine
    Zucker School of Medicine
    Hofstra/Northwell
    Medical Director of Recognition and Prevention Program
    The Zucker Hillside Hospital
    Glen Oaks, New York

    Disclosures

    Disclosure: Christoph Correll, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acadia; Alkermes; Allergan; Angelini; Axsome; Gedeon Richter; Gerson Lehrman Group; Indivior; IntraCellular Therapies; Janssen/J&J; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Medscape; Merck; Mitsubishi Tanabe Pharma; Mylan; Neurocrine; Noven; Otsuka; Pfizer; Recordati; Rovi; Servier; Sumitomo Dainippon; Sunovion; Supernus; Takeda; Teva
    Served as a speaker or a member of a speakers bureau for: Allergan; Angelini; Gedeon Richter; Janssen/J&J; Lundbeck; Otsuka; Pfizer; Recordati; Sunovion
    Received grants for clinical research from: Janssen; Takeda
    Owns stock, stock options, or bonds from: LB Pharma

  • Melissa DelBello, MD, MS

    Dr Stanley and Mickey Kaplan Professor and Chair of Psychiatry and Behavioral Neuroscience
    University of Cincinnati
    Cincinnati, Ohio

    Disclosures

    Disclosure: Melissa DelBello, MD, MS, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alkermes, Inc.; Allergan, Inc.; AssureRx Health, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lundbeck, Inc.; Neuronetics; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.
    Received grants for clinical research from: ACADIA Pharmaceuticals Inc.; Allergan, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lundbeck, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.

  • Joseph Goldberg, MD

    Clinical Professor of Psychiatry
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Disclosure: Joseph Goldberg, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BioXcel; Otsuka; Sage Pharmaceuticals; Sunovion; WebMD
    Served as a speaker or a member of a speakers bureau for: Allergan; Intracellular Therapies; Otsuka; Sunovion

  • Diana O. Perkins, MD, MPH

    Professor of Psychiatry
    Medical Director, OASIS (Outreach and Support Intervention Service)
    University of North Carolina, Chapel Hill School of Medicine
    Chapel Hill, North Carolina

    Disclosures

    Disclosure: Diana O. Perkins, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alkermes, Inc.
    Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.

  • Amanda J. Simonton, PhD, APRN, PMHNP-BC

    Clinical Assistant Professor
    University of Texas at Austin School of Nursing
    Austin, Texas

    Disclosures

    Disclosure: Amanda Simonton, PhD, APRN, PMHNP-BC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Creative Educational Concepts
    Served as a speaker or a member of a speakers bureau for: College of Pharmacy, University of Texas at Austin

Editors

  • Rob Lowney

    Principal/Managing Director, CMEology

    Disclosures

    Disclosure: Rob Lowney has disclosed no relevant financial relationships.

  • Stephen Strudwick, PhD

    Scientific Director, CMEology

    Disclosures

    Disclosure: Stephen Strudwick, PhD, has disclosed no relevant financial relationships.

  • Meg Monday

    Senior Director, Content Development

    Disclosures

    Disclosure: Meg Monday has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Presented through a collaboration between CMEology and Medscape Education.



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Balancing Efficacy and Safety in Schizophrenia: Current and Emerging Approaches

Authors: Christoph U. Correll, MDFaculty and Disclosures

CME / ABIM MOC Released: 8/2/2021; Reviewed and Renewed: 9/14/2022

Valid for credit through: 9/14/2023

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.

  • Print